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Commun i c a t i o n
I N T RODUC T I ON
The early infantile epileptic encephalopathies (EIEEs) 
are a group of disorders characterized by intractable 
seizures, persistently abnormal cortical function, and 
unfavorable neurodevelopmental outcomes (Berg et al., 
2010; Nabbout and Dulac, 2012; Covanis, 2014). The 
etiologies include structural brain malformations, ac-
quired brain insults, and inborn errors of metabolism 
(Nabbout and Dulac, 2012; Covanis, 2014). A significant 
proportion of these cases remain without molecular di-
agnosis despite extensive investigation. Recently, variants 
in genes encoding voltage-gated potassium (Kv) chan-
nels, including KCNQ2 (Singh et al., 1998; Weckhuysen 
et al., 2013), KCNQ3 (Cavaretta et al., 2014), and KCNB1 
(Srivastava et al., 2014; Torkamani et al., 2014), have 
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been associated with EIEE (Maljevic and Lerche, 2014). 
KCNB1 encodes the Kv2.1 pore-forming and voltage-
sensing  subunit of a delayed rectifier Kv channel that 
is expressed in diverse neuron types (Trimmer, 2015). 
Kv2.1 is highly expressed in the neurons throughout 
the brain and forms the principal delayed rectifier cur-
rent of many neuron types (Murakoshi and Trimmer, 
1999; Du et al., 2000; Malin and Nerbonne, 2002; Guan 
et al., 2007; Mandikian et al., 2014). Kv2.1 plays impor-
tant roles in regulating neuronal excitability, contribut-
ing to action potential repolarization (Liu and Bean, 
2014) and dynamic modulation of neuronal activity 
(Misonou et al., 2004, 2008; Fox et al., 2013). In addi-
tion to its electrical roles in neurons, Kv2.1 plays a less 
understood structural role in neurons. Kv2.1 channels 
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The epileptic encephalopathies are a group of highly heterogeneous genetic disorders. The majority of disease-
causing mutations alter genes encoding voltage-gated ion channels, neurotransmitter receptors, or synaptic pro-
teins. We have identified a novel de novo pathogenic K+ channel variant in an idiopathic epileptic encephalopathy 
family. Here, we report the effects of this mutation on channel function and heterologous expression in cell lines. 
We present a case report of infantile epileptic encephalopathy in a young girl, and trio-exome sequencing to de-
termine the genetic etiology of her disorder. The patient was heterozygous for a de novo missense variant in the 
coding region of the KCNB1 gene, c.1133T>C. The variant encodes a V378A mutation in the  subunit of the Kv2.1 
voltage-gated K+ channel, which is expressed at high levels in central neurons and is an important regulator of 
neuronal excitability. We found that expression of the V378A variant results in voltage-activated currents that are 
sensitive to the selective Kv2 channel blocker guangxitoxin-1E. These voltage-activated Kv2.1 V378A currents were 
nonselective among monovalent cations. Striking cell background–dependent differences in expression and sub-
cellular localization of the V378A mutation were observed in heterologous cells. Further, coexpression of V378A 
subunits and wild-type Kv2.1 subunits reciprocally affects their respective trafficking characteristics. A recent study 
reported epileptic encephalopathy-linked missense variants that render Kv2.1 a tonically activated, nonselective 
cation channel that is not voltage activated. Our findings strengthen the correlation between mutations that result 
in loss of Kv2.1 ion selectivity and development of epileptic encephalopathy. However, the strong voltage sensitivity 
of currents from the V378A mutant indicates that the loss of voltage-sensitive gating seen in all other reported 
disease mutants is not required for an epileptic encephalopathy phenotype. In addition to electrophysiological 
differences, we suggest that defects in expression and subcellular localization of Kv2.1 V378A channels could con-
tribute to the pathophysiology of this KCNB1 variant.
© 2015 Thiffault et al. This article is distributed under the terms of an Attribution–Non-
commercial–Share Alike–No Mirror Sites license for the first six months after the publication 
date (see http://www.rupress.org/terms). After six months it is available under a Creative 
Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as de-
scribed at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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target coverage of 135×, which identified 170,000 nucleotide 
variants. Variants were filtered to 1% minor allele frequency in an 
internal database of 2,129 samples, and then prioritized by the 
American College of Medical Genetics categorization (Richards 
et al., 2008), OMIM identity, and phenotypic assessment. The pa-
tient was found to have a heterozygous missense variant in exon 2 
of KCNB1, c.1133T>C (p.V378A). The variant was confirmed by 
Sanger sequencing. Family relationships were confirmed by seg-
regation analysis of rare single-nucleotide variants on several 
chromosomal regions. The KCNB1 variant was absent from the 
patient’s parents, the NHLBI Exome Sequencing Project, and an 
internal variant database.
Plasmids
A single T1133C point mutation was introduced into the hKv2.1/
pRC/CMV plasmid (Zhang et al., 2003) encoding human Kv2.1 
(RefSeq accession no. NP_004966) to generate the V378A plas-
mid. The modification was confirmed by sequencing. Where 
noted, an empty RBG4 plasmid was cotransfected to normalize 
total amount of DNA/transfection, or an empty EGFP-C1 plasmid 
(no. 6084-1; Takara Bio Inc.) was cotransfected to provide GFP 
expression in transfected cells. Kv2.1 C237 was a previously de-
scribed variant of rat Kv2.1 (Lim et al., 2000) in the pCGN plas-
mid (Tanaka and Herr, 1990). Human wild-type and V378A 
mutant plasmid DNA used in all experiments was transformed 
and purified identically and contemporaneously using a Maxi-
prep purification kit (QIAGEN).
Cell culture and transfection
All cell lines were grown in a humidified incubator at 37°C and 
5% CO2. COS-1 cells were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% bovine calf serum (Hy-
Clone), 1% penicillin/streptomycin, and 1× GlutaMAX (Thermo 
Fisher Scientific). COS-1 cells were split to 10% confluence and 
then transfected in Opti-MEM (Thermo Fisher Scientific) 24 h 
later with the constructs described above using LipofectAMINE 
2000 (Thermo Fisher Scientific) according to the manufactur-
er’s protocol. Media was replaced 4 h after transfection. COS-1 
cells were used 40–48 h after transfection. CHO-K1 (CCL-61; 
ATCC) cells were maintained in tissue culture–treated polysty-
rene dishes (BioLite; Thermo Fisher Scientific), Ham’s F12 
media (MT-10-080-CV; Corning) containing 10% FBS (GemCell), 
and 1% penicillin/streptomycin (Thermo Fisher Scientific). 
Cells were transfected in Ham’s F12 media with LipofectAMINE 
2000 according to the manufacturer’s protocol, using 2 µl Lipo-
fectamine, and 1 µg DNA per milliliter media. Media was replaced 
4–6 h after transfection, and cells were used for experiments 
2 d later.
Electrophysiology
Whole-cell voltage-clamp recordings were used to measure cur-
rents from Kv2.1 channels expressed in CHO-K1 cells. Cells were 
harvested by scraping in divalent-free PBS with 1 mM EDTA, pel-
leted at 650 g for 7 min, resuspended in CHO-SFMII media 
(Thermo Fisher Scientific) supplemented with 25 mM HEPES, 
pH 7.3, and rotated in a polypropylene tube at room temperature 
until use. Aliquots of cell suspension were added to a recording 
chamber and rinsed with external solution 5 or more minutes 
before recording. The external (bath) solution contained (mM): 
3.5 KCl, 155 NaCl, 1.5 CaCl2, 1 MgCl2, and 10 HEPES, adjusted to 
pH 7.4 with NaOH. The internal (pipet) solution contained 
(mM): 50 KF, 70 KCl, 35 KOH, 5 EGTA, and 50 HEPES, adjusted to 
pH 7.3 with HCl. A measured liquid junction potential of 12 mV 
was corrected. The Kv2 inhibitor GxTX is the guangxitoxin-1E 
toxin with methionine 35 replaced by norleucine, synthesized as 
described previously (Tilley et al., 2014). GxTX was added by 
flushing 200 µl through a low volume recording chamber (R-24N; 
form large clusters on the cell body, proximal dendrites, 
and axon initial segments of neurons that represent plasma 
membrane–ER junctions (Trimmer, 1991; Antonucci 
et al., 2001; King et al., 2014; Fox et al., 2015). The major-
ity of these clustered channels are reported to be non-
conducting (O’Connell et al., 2010; Fox et al., 2013). 
The presence of Kv2.1 drives recruitment of other proteins 
to these clusters, indicating that subcellular localization 
of Kv2.1 could have neurophysiological consequences 
beyond electrical signaling (Antonucci et al., 2001; Fox 
et al., 2015).
Genetic defects in Kv2.1 lead to neurological conse-
quences. Mice lacking Kv2.1 are strikingly hyperactive, 
defective in spatial learning, hypersensitive to convulsants, 
and exhibit accelerated seizure progression (Speca et al., 
2014). Human genetic evidence indicates that muta-
tions in Kv2.1 can lead to EIEE. De novo missense vari-
ants in KCNB1 were initially reported in three patients 
with EIEE with associated cognitive and motor dysfunc-
tion (Torkamani et al., 2014). These variants were lo-
cated within the Kv2.1 pore domain and associated with 
a loss of ion selectivity and voltage-sensitive gating, re-
sulting in a tonic inward cation conductance. A fourth 
patient was recently identified through whole-exome 
sequencing (Srivastava et al., 2014). In this Communi-
cation, we report the fifth patient with a novel de novo 
variant in the KCNB1 gene, c.1133T>C (p.V378A), located 
in the Kv2.1 pore domain, and a basic characterization 
of the effects of the mutation on channel expression and 
function. As this is the original reporting of this KCNB1 
variant, we present a clinical history of the patient. We 
then present functional evidence regarding the unique 
electrophysiological activity and subcellular localization 
of this Kv2.1 channel variant that could provide addi-
tional insight into the pathophysiological molecular 
mechanisms underlying the neurological defects seen 
in EIEE patients.
MAT E R I A L S  AND  M E THOD S
Clinical reporting
Presentation of patient information, clinical findings, diagnostic 
assessment, therapeutic intervention, and outcomes conform to 
standardized clinical case report guidelines (Gagnier et al., 2013). 
All human studies were approved by the institutional review 
board of the Children’s Mercy Hospital, and the parents gave 
informed consent for participation in the study.
Genetic analysis
DNA was extracted from peripheral blood of patient CMH574 
and her two healthy parents (CMH575 and CMH576) and pre-
pared with the Nextera Expanded Exome kit (llumina). Samples 
were sequenced on a HiSeq 2000 instrument with TruSeq SBS v3 
reagents (Illumina), yielding paired 100 nucleotide reads. Align-
ment, variant calling, and analysis were performed as reported 
previously (Bell et al., 2011; Saunders et al., 2012). Patient CMH574 
was sequenced to a depth of 10.4 gigabases resulting in median 
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of blots was performed on a FluorChem Q imager (Protein Sim-
ple), using the multiplex band analysis tool (version 3.4.0) to 
assess Kv2.1 fluorescence intensity after background subtrac-
tion. Kv2.1 expression intensity was then normalized to either 
the actin or mortalin-loading control for each sample before 
statistical analysis.
Analysis and statistics
GraphPad Prism (version 6.0b) or IgorPro (version 6; WaveMet-
rics) software was used for presentation and statistical analyses of 
microscopy or electrophysiology data, respectively. Data are pre-
sented as means ± SEM.
Accession numbers
The RefSeq accession numbers for KCNB1 variants reported in 
this paper are NM_004975.2 and NP_004966.1.
R E S U L T S
Clinical data
A 3-yr-old Caucasian female presented with intractable 
multifocal epilepsy, global developmental delay, and 
difficulty feeding. Prenatal history was unremarkable; 
delivery was at full-term with a normal neonatal period. 
Her first recognized seizure at 13 mo lasted for 10 min. 
EEG recordings revealed intermittent left and right 
temporal/temporal parietal spike, polyspike and slow 
wave discharges, and intermittent superimposed left and 
right temporal focal slowing. Starting in the first months 
of life, she was easily startled, blinked repeatedly, and 
had episodes of staring, suggesting an earlier onset of 
seizures. Brain MRI at 13 and 18 mo were normal.
She developed a social smile at age 3 mo and rolled 
between 6 and 10 mo of life. Between 13 and 15 mo, she 
began to regress significantly in skills and developed 
oral motor dysphagia requiring liquid formula supple-
mentation. At 15 mo, she was able to sit with some sup-
port, and by age 3 yr she was able to sit independently 
but could not stand or walk. She never developed speech, 
only limited vocalization and inappropriate laughter. At 
age 3 yr she functioned at a 5–8-mo developmental level. 
Her seizures were refractory to numerous medications 
including Keppra, Depakote, Clobazam, Zonisamide, 
and Lamictal. After implementation of the ketogenic 
diet, she was initially seizure free for 6 mo, followed by 
breakthrough seizures ranging from 1 to >20 per day. 
Relevant family history included febrile seizures in the 
patient’s mother until age 9. An extensive workup was 
normal, including: high resolution karyotype, CGH mi-
croarray, methylation studies for Angelman syndrome, 
palmitoyl protein thioesterase 1 and tripeptidyl peptidase 
1 enzymes, comprehensive epilepsy gene panel (53 genes; 
no. 523; GeneDX), sequence and deletion/duplication 
analysis, carbohydrate-deficient transferrin analysis, 
N-glycan structural analysis, very long chain fatty acids, 
plasma amino acids, 7-dehydrocholesterol, urine organic 
acids, and oligosaccharides.
Warner). Pipettes were pulled from thin-wall borosilicate glass 
(no. BF150-110-7.5HP; Sutter Instrument). Pipette tip resistances 
were <3 MΩ. Recordings were performed at room temperature 
(21–23°C). Voltage clamp was achieved with an amplifier (Axon 
Axopatch 200B; Molecular Devices) run by Patchmaster software 
(HEKA). The holding potential was 100 mV. Series resistance 
compensation was used when needed to constrain voltage error 
to <10 mV. Capacitance and ohmic leak were subtracted using a 
P/5 protocol. Recordings were low-pass filtered at 10 kHz and 
digitized at 100 kHz. Current traces were digitally filtered at 2 kHz 
for display in figures. Data were analyzed and plotted with Igor-
Pro software (Version 6; WaveMetrics). Conductance was mea-
sured from tail currents immediately after a 100-ms step to the 
indicated voltage; tails were analyzed at 0 mV for wild-type chan-
nels and at 100 mV for V378A. Fits with the fourth power of a 
Boltzmann distribution are described previously (Sack et al., 2004; 
Tilley et al., 2014). Conductance data shown are normalized to the 
peak amplitude of the fit; Vmid reported is the voltage when the 
fit reaches half-maximal amplitude. Ion selectivity experiments 
were conducted by exchange of external solution. 155 mM NaCl 
was replaced by RbCl, CsCl, KCl, NH4Cl, or NMDG + HCl, and 
adjusting pH to 7.4 with NMDG. Ionic permeability was calcu-
lated from the reversal potential with the indicated ion in the 
external solution, as described previously (Heginbotham et al., 
1994). The ratio PX/PK is the permeability of the indicated ion 
normalized to K+.
Immunofluorescence immunocytochemistry
COS-1 and CHO-K1 cells grown on poly-l-lysine–coated glass 
coverslips were fixed for 15 min in ice-cold 4% formaldehyde pre-
pared fresh from paraformaldehyde, 4% sucrose, and 0.1% 
Triton X-100 in DPBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, and 1.76 mM KH2PO4, pH 7.4) with 1 mM CaCl2 and 
1 mM MgCl2, or were fixed for 30 min in 4% formaldehyde pre-
pared fresh from paraformaldehyde and 4% sucrose in DPBS. 
Cells were blocked and permeabilized with 3% (wt/vol) bovine 
serum albumin and 0.1% Triton X-100 in DPBS for 60 min, and 
then coverslips were incubated with primary antibody overnight 
at 4°C (anti-Kv2.1 K89/34 IgG1: 1:20 dilution of tissue culture 
supernatant, Research Resource Identifier [RRID]: AB_10672253; 
anti-GFP N86/38 IgG2a: 1:5 dilution of tissue culture superna-
tant, RRID: AB_10671955; both from the UC Davis/National 
Institutes of Health [NIH] NeuroMab Facility; anti-HA, RRID: 
AB_2532070). Primary antibodies were detected with appropriate 
mouse IgG subclass-specific fluorescent secondary antibodies 
(A21127, A21131, A21121, and A21147; 1:2,000; Thermo Fisher 
Scientific) and Hoechst 33258 stain (H21491; Thermo Fisher Sci-
entific). Coverslips were washed again in DPBS and mounted 
using Prolong Gold (P36930; Thermo Fisher Scientific). Images 
were acquired using an AxioCam HRm high resolution CCD 
camera installed on an AxioObserver Z1 microscope with a 63×, 
1.3-numerical aperture (NA) lens or a 20×, 0.8-NA lens and an 
Apotome controlled by Axiovision software (Carl Zeiss). Images 
were processed identically in Photoshop to maintain consistency 
between samples.
Immunoblots
Cell lysates were prepared as described previously (Shi et al., 
1994). Proteins were separated by 9% SDS-PAGE and transferred 
to nitrocellulose membranes. Blots were probed with rabbit anti-
Kv2.1 (1:500; KC; RRID: AB_2315767) and as loading controls 
mouse anti-mortalin (1:2, N52A/42 tissue culture supernatant; 
RRID: AB_10674108, from the UC Davis/NIH NeuroMab Facil-
ity) or rabbit anti-actin (1.0 µg/ml; RRID: AB_630834; sc-1616R; 
Santa Cruz Biotechnology, Inc.) for 60 min in TBS, followed by 
incubation with appropriate fluorescently labeled secondary anti-
body (1:1,500) for an additional 60 min. Imaging and quantitation 
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voltage step, the outward currents from V378A exhibited 
a marked peak followed by decay, indicating that inacti-
vation occurs at a faster rate in the mutant channels; 
upon return to the negative holding voltage, V378A dis-
played larger inward tail currents (Fig. 1, A and B). The 
voltage dependence of channel gating was reconstructed 
from tail currents after depolarizing voltage stimuli 
(Fig. 1 C). This analysis indicated that voltage-dependent 
gating of the V378A variant was distinct from wild type 
yet had a similar steepness when fitted with a Boltzmann 
distribution. The incidence of voltage-activated current 
in GFP+ cells was low compared with wild-type Kv2.1; 
voltage-activated currents >400 pA at 60 mV were appar-
ent in only 20% (18/88) of V378A GFP+ cells recorded, 
compared with 68% (38/56) for cells transfected with 
wild-type Kv2.1. As endogenous voltage-gated currents 
can occasionally be present in CHO-K1 cells (Lalik et al., 
1993), we tested whether the currents from V378A-
transfected cells had pharmacology typical of Kv2.1 chan-
nels. The tarantula venom peptide toxin GxTX is the 
most thoroughly validated Kv2.1 inhibitor (Herrington 
et al., 2006; Li et al., 2013; Liu and Bean, 2014) and 
does not bind to CHO-K1 cells lacking Kv2.1 channels 
(Tilley et al., 2014). Currents from both wild-type Kv2.1 
and V378A cells were inhibited by GxTX (Fig. 1, D–F), 
corroborating the conclusion that the voltage-activated 
currents with large inward tail currents originated from 
Kv2.1 channels.
Kv2.1 V378A channels are not K+ selective
The reversal potential of Kv2.1 was notably altered by 
the V378A variant. Distinct from wild-type Kv2.1 chan-
nels, V378A channels produced large inward tail cur-
rents at voltages much more positive than the calculated 
K+ reversal potential of 97 mV (Fig. 2, A and B), sug-
gesting that ions other than K+, such as Na+, might per-
meate the mutant channels. To test this hypothesis, we 
Whole-exome sequencing analyses reveal a novel de novo 
KCNB1 missense variant
The patient was found to be heterozygous for a de novo 
missense variant, 1133T>C, in exon 2 of KCNB1, which 
encodes the Kv2.1 channel. This variant affects codon 
378, a highly conserved amino acid residue in the pore 
helix of the Kv2.1 channel. The mutation substitutes va-
line 378 with alanine, the disruption of which is predicted 
by SIFT (Kumar et al., 2009) and PolyPhen2 (Adzhubei 
et al., 2010) to be damaging. Valine 378 is the amino 
acid position just before the “GYG” motif, encoded by 
residues 379–381, which defines the K+ selectivity filter. 
Previous studies found that a valine to alanine mutation 
at the equivalent residue in the Drosophila melanogaster 
Shaker Kv channel results in voltage-activated channels 
exhibiting loss of ion selectivity (Heginbotham et al., 
1994), suggesting that degenerate ion permissiveness 
may underlie the functional defect in our patient.
Kv2.1 V378A forms voltage-activated ion channels
To determine whether the V378A variant alters the func-
tion of the Kv2.1 channel, we expressed wild-type and 
mutant human Kv2.1 channels in CHO-K1 cells and 
examined whole-cell current under voltage clamp. Co-
transfection of the wild-type Kv2.1 construct with a GFP 
construct resulted in voltage-activated currents in green 
fluorescent cells (GFP+). When voltage was stepped 
positive from a negative holding potential, outward cur-
rents resulted after a delay, with a sigmoid waveform 
(Fig. 1 A) indicative of the human voltage-activated de-
layed rectifier Kv2.1 channel (Ikeda et al., 1992; Zhang 
et al., 2003; Torkamani et al., 2014). Transfections of 
the V378A construct also resulted in voltage-activated 
currents (Fig. 1 B). These currents are distinct from 
the previously described EIEE-linked KCNB1 variants, 
S347R, G379R and T374I, none of which retained volt-
age activation (Torkamani et al., 2014). After a positive 
Figure 1. The Kv2.1 V378A mutant produces 
voltage-activated currents. Whole-cell patch-clamp 
recordings from transiently transfected CHO-K1 
cells. Currents are responses to voltage steps 
from a holding potential of 100 mV. (A) Kv2.1 
wild-type currents were stepped for 100 ms to 
80, 40, 0, 40, or 80 mV, and then returned 
to 100 mV. (B) Kv2.1 V378A currents elicited 
by the same protocol as A. (C) Conductance– 
voltage relation of Kv2.1 wild-type (open cir-
cles) and V378A (filled circles) measured from 
tail currents after 100-ms depolarizing steps to 
the indicated voltage. Lines are fourth-power 
Boltzmann fits. Wild-type Vmid = 8 mV and z = 0.9 
e+; V378A Vmid = 21 mV and z = 1.1 e+. (D) Cur-
rent from wild-type Kv2.1. 100-ms step to 40 mV. 
Thin trace, control; thick trace, 100 nM GxTX. 
(E) Kv2.1 V378A currents, with same protocols 
as D. (F) Summary of inhibition by 100 nM GxTX 
at 40 mV. Wild-type, n = 4; V378A, n = 3. Error 
bars represent means ± SEM.
 Thiffault et al. 403
currents recorded from V378A/wild-type Kv2.1 cotrans-
fections had ionic selectivity similar to wild-type Kv2.1 
(Fig. 2 F). This suggests that currents through channels 
containing V378A subunits could be small relative to 
channels containing only wild-type subunits, and/or 
that heteromeric wild-type/mutant channels may not 
localize efficiently to the plasma membrane.
The V378A mutation alters Kv2.1 expression
The changes in function of the V378A mutant channel 
potentially underlie the human disease phenotype, as 
proposed for other Kv2.1 pore mutations (Torkamani 
et al., 2014). However, it was notable that V378A chan-
nels failed to produce significant current in the major-
ity of patch-clamped cells, suggesting an alteration in 
protein expression or localization. Expression and lo-
calization of wild-type and V378A channels were tested 
by immunofluorescence labeling of transfected cells with 
specific anti-Kv2.1 antibodies. CHO-K1 cells were tran-
siently cotransfected with GFP and wild-type Kv2.1 or 
V378A. Multiplex immunofluorescence labeling (Fig. 3 A) 
indicated that although the incidence of GFP expres-
sion was similar between cultures transfected with wild-
type and V378A plasmids, fewer cells expressed V378A 
protein relative to wild-type Kv2.1. Specifically, although 
GFP was expressed in 20% of cells cotransfected with 
either Kv2.1 wild-type or V378A plasmids, detectable 
substituted extracellular sodium with NMDG+, a large 
cation that cannot permeate most ion channels. NMDG+ 
substitution reduced the large inward tail currents. This 
indicates that Na+ was indeed permeating the V378A 
channel (Fig. 2, B, D, and E). To test if the V378A chan-
nel had completely lost the ability to select between 
monovalent cations, we measured the relative permea-
bilities of K+, Na+, NMDG+, Rb+, Cs+, and NH4+. Signifi-
cantly greater permeability was seen for Na+, Cs+, and 
NH4+ (Fig. 2 F). None of the metal ions had a permea-
bility distinguishable from K+. This is similar to the 
effects of the homologous mutation in the Shaker K+ 
channel (V443A) (Heginbotham et al., 1994). The loss of 
ionic selectivity suggests that in vivo, voltage activation of 
Kv2.1 V378A channels would result in Na+ flux through 
the channel along with K+, eliminating the ability of the 
channel to repolarize cells. Instead, Kv2.1 V378A would 
likely depolarize cells upon channel opening.
To generate a channel expression profile that could 
better mimic the EIEE patient heterozygous for Kv2.1 
V378A, we cotransfected equal amounts of Kv2.1 wild-
type and V378A subunits. The proportion of cotrans-
fected cells with distinct delayed rectifier current (34/78 
of GFP+ cells, 44%, had voltage-activated currents >400 
pA at 60 mV) was intermediate between those seen 
upon expression of wild-type Kv2.1 and V378A sub-
units alone (see above). However, the voltage-activated 
Figure 2. The Kv2.1 V378A mutant is a 
nonselective cation channel. Whole-cell 
patch-clamp recordings from transiently 
transfected CHO-K1 cells. Currents are 
responses to voltage steps from a hold-
ing potential of 100 mV. (A) Kv2.1 
wild-type currents. 50-ms steps to 
40 mV, and then to 120, 80, 40, 
0, or 40 mV. (B) Kv2.1 V378A cur-
rents elicited by the same protocol as A. 
(C and D) Same cell and protocol as in 
A and B but with external Na+ replaced 
by NMDG+. (E) Instantaneous current 
level from Kv2.1 V378A at the indicated 
voltage after a 50-ms step to 40 mV in 
control external (black) or NMDG ex-
ternal (gray). (F) Permeability ratios 
for the indicated ion over K+, calculated 
from the reversal potential when exter-
nal Na+ is replaced with the indicated 
ion. Cotransfection delivered an equal 
amount of wild-type and V378A DNA. 
*, P < 0.01, compared with wild type by 
two-tailed Mann–Whitney U test. Error 
bars represent means ± SEM.
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The distinct differences in subcellular localization of 
the mutant and wild-type Kv2.1 isoforms raised ques-
tions as to the effects of their coexpression, as occurs in 
immunolabeling for V378A protein was found in a sig-
nificantly lower percentage (1.6%) of cells than wild-
type Kv2.1 (7.2%; Fig. 3 B). Thus, the incidence of Kv2.1 
protein expression and voltage-activated current (see 
above) were both reduced by the V378A mutation. No-
tably, there were no obvious differences in localization 
of the V378A protein relative to wild-type Kv2.1 in CHO-
K1 cells (Fig. 3 A). Immunoblot analysis also indicated 
that total levels of V378A protein were lower than wild-
type Kv2.1 (Fig. 3, C and D). Sodium influx can be toxic 
to cells, potentially reducing protein expression. To test 
whether reduced V378A expression is a response to per-
meation through the nonselective channels, transfected 
CHO-K1 cells were cultured in the presence of GxTX, 
which inhibits ion flux through both Kv2.1 wild-type and 
V378A (Fig. 1 F). However, GxTX treatment failed to 
rescue the reduced expression level of the V378A mu-
tant in CHO-K1 cells, as assayed by immunoblot (Fig. 3, 
C and D).
To test whether the reduced expression of V378A 
channels seen in CHO-K1 cells was a generalized phe-
nomenon, we examined the expression of V378A in an-
other mammalian cell type, COS-1, in which we have 
extensively characterized the subcellular localization of 
rat Kv2.1 (e.g., Shi et al., 1994). Significant differences 
were also observed in Kv2.1 expression incidence be-
tween wild-type and V378A mutant Kv2.1 in COS-1 cells, 
although the fractional decrement with V378A was not 
as profound as in CHO-K1 cells (Fig. 4 A). No signifi-
cant decrement in expression incidence was observed 
when wild-type and V378A subunits were coexpressed 
(Fig. 4 A). The subcellular localization of the V378A 
mutant was distinct from wild-type Kv2.1 in COS-1 cells. 
Wild-type Kv2.1 was observed at/near the plasma mem-
brane, as described previously for rat Kv2.1 in this cell 
type (Shi et al., 1994). This plasma membrane pattern 
was observed only in a subset of cells expressing V378A, 
as a significant fraction of cells exhibited little to no ex-
pression at/near the plasma membrane (Fig. 4 B). Re-
markably, incubation of COS-1 cells with GxTX rescued 
the expression pattern of the V378A mutant, changing 
the localization to a plasma membrane–like pattern 
more typical of wild-type Kv2.1 (Fig. 4, B and C). V378A-
expressing cells with no plasma membrane–associated 
labeling exhibited robust intracellular immunofluores-
cence labeling that overlapped with Lens culinaris lectin 
labeling, a marker of the Golgi apparatus (Hsu et al., 
1992; Ridgway et al., 1992; Fig. 4 D). Immunoblot analy-
ses of COS-1 cells revealed lower levels of the V378A 
mutant protein, similar to what was observed in CHO-
K1 cells (Fig. 3, C and D). Consistent with effects 
observed by immunofluorescence labeling, effects of 
treatment with GxTX could also be seen by immuno-
blotting of COS-1 cells, which showed that the reduced 
level of V378A protein expression was restored to that of 
wild-type Kv2.1 upon GxTX treatment (Fig. 4, E and F).
Figure 3. Decreased Kv2.1 V378A expression and lack of res-
cue by GxTX in CHO-K1 cells. (A) Multiplex imaging of EGFP 
(green), Kv2.1 (red), and Hoechst 33258 (blue, to label nuclei), 
indicating reduced incidence of Kv2.1 V378A expression com-
pared with wild-type Kv2.1. Bar, 10 µm. (B) Similar transfection 
efficiency of EGFP but significantly lower transfection efficiency 
of Kv2.1 V378A compared with wild-type Kv2.1, as measured by 
immunofluorescence labeling (n = 3 independent samples per 
treatment). (C) Immunoblot analysis of CHO-K1 cell extracts cul-
tured in the absence or presence of 400 nM GxTX, showing re-
duced levels of V378A Kv2.1 protein that is not rescued by 400 nM 
GxTX treatment. Actin was used as a loading control. (D) Quanti-
tation of immunoblot analyses demonstrating significantly lower 
expression and lack of GxTX rescue in Kv2.1 V378A-expressing 
cells relative to wild type (n = 3 per treatment). **, P < 0.01, by 
two-way ANOVA followed by post-hoc Tukey tests. Error bars rep-
resent means ± SEM.
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heterozygous patients. To test how expression of mu-
tant V378A subunits could impact the surface localiza-
tion of wild-type subunits, and vice versa, we exploited 
an epitope-tagged Kv2.1 C-terminal truncation mutant 
C237, which is wild type throughout, including at the 
pore region, and has a subcellular localization indistin-
guishable from wild-type Kv2.1 (Lim et al., 2000) but 
lacks immunoreactivity with the anti-Kv2.1 antibody 
used here to detect the expression of the V378A mu-
tant. The wild-type Kv2.1 C237 truncation mutant was 
coexpressed with human Kv2.1 V378A. Immunolabel-
ing for antibodies that selectively recognize one or the 
other allowed us to separately determine the subcellular 
localization of the wild-type and mutant Kv2.1 subunits 
in coexpressing cells. Coexpression revealed a reciprocal 
effect of wild-type and mutant subunits on subcellular 
localization, in that each was impacted by the presence 
of the other. Specifically, a prominent decrease in plasma 
membrane–associated immunolabeling for C237, and 
an increased intracellular retention, was observed upon 
its coexpression with V378A. Moreover, coexpression of 
C237 with the V378A mutant yielded an increase in 
V378A plasma membrane–associated immunolabeling 
(Fig. 5 A). At the individual cell level, the distinct sub-
cellular localizations of C237 with the V378A seen in 
singly expressing cells became more similar upon coex-
pression, with substantial overlap of immunolabeling for 
both isoforms in both intracellular and plasma mem-
brane compartments (Fig. 5 B).
D I S C U S S I ON
Trio-exome sequencing has become an effective tool 
for EIEE diagnosis, with de novo variants in ion chan-
nels playing a prominent role (Weckhuysen et al., 2013; 
EuroEPINOMICS-RES, 2014; Dyment et al., 2015). 
Consistent with their extreme genomic, proteomic, and 
functional diversity, Kv channels have been implicated 
in an exceptionally wide variety of genetic and autoim-
mune neurological disorders, including episodic ataxia, 
Figure 4. Altered subcellular localization and rescue of expres-
sion of Kv2.1 V378A in COS-1 cells. (A) Transfection efficiency 
of wild-type, V378A, and an equal amount of wild-type + V378A 
(Het) in COS-1 cells, as measured by immunofluorescence. Data 
are from at least 115 cells per independent sample (n = 3 for each 
treatment). Data are the mean ± SEM. *, P < 0.05 (two-tailed un-
paired t test). (B) Quantitation of surface expression of Kv2.1 in 
the absence or presence of 400 nM GxTX (n = 3 per treatment). 
(C) Multiplex fluorescence labeling for Kv2.1 (red) and Hoechst 
33258 (blue) in cells cultured in the absence or presence of 
400 nM GxTX. Wild-type Kv2.1 expression was robust and asso-
ciated with the plasma membrane regardless of treatment. In 
contrast, V378A expression was, in a significant fraction of cells, 
restricted to an intracellular perinuclear compartment consistent 
with the Golgi apparatus, whereas V378A cells cultured in the pres-
ence of 400 nM GxTX had more plasma membrane–associated 
labeling, resembling that of wild-type Kv2.1. Bar, 10 µm. (D) Mul-
tiplex fluorescence labeling of a Kv2.1 V378A-expressing cell for 
Kv2.1 (red), the Golgi marker Lens culinaris lectin (green), and 
Hoechst 33258 (blue, to label nuclei) suggests a concentration of 
Kv2.1 V378A in the Golgi apparatus. Insets are a higher magni-
fication of the perinuclear region. Bar, 10 µm. (E) Immunoblot 
analysis of COS-1 cell extracts cultured in the absence or presence 
of 400 nM GxTX, showing reduced levels of V378A mutant Kv2.1 
protein that is rescued by GxTX. Mortalin was used as a loading 
control. (F) Quantitation of Kv2.1 immunoblot expression nor-
malized to the mortalin loading control indicates a significantly 
decreased level of expression of Kv2.1 V378A relative to wild-type 
Kv2.1. Culturing cells in the presence of 400 nM GxTX rescues 
the decreased V378A expression level in this cell type (n = 3 
per treatment). *, P < 0.05, by two-way ANOVA followed by 
post-hoc Tukey tests.
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The de novo V378A variant in KCNB1 fundamentally 
changes the ion selectivity of Kv2.1 channels from 
potassium-selective to nonselective cation channels, as 
was also demonstrated for three previously reported 
de novo KCNB1 mutations (Torkamani et al., 2014). 
To date, all reported missense variants are located 
within the pore domain of Kv2.1 (Srivastava et al., 2014; 
Torkamani et al., 2014). All variants that have been 
studied in heterologous expression systems reported 
here and previously (Torkamani et al., 2014) have formed 
channels with loss of K+ selectivity, yielding a depolarizing 
inward cation conductance at negative voltages. Nota-
bly, the variant we report here is functionally distinct 
from those whose currents have been reported previously, 
in that the V378A channel is gated by voltage, whereas 
the other disease-associated Kv2.1 mutations charac-
terized to date remain constitutively open (Torkamani 
et al., 2014). V378A channels are voltage dependent 
and sensitive to the Kv2-specific toxin GxTX, provid-
ing compelling evidence that the nonselective cation 
currents recorded from cells expressing the mutant chan-
nels are from bona fide Kv2.1 channels. These findings 
support the previously proposed pathogenic role for 
altered ionic selectivity, yet suggest that the abroga-
tion of voltage-activated gating reported for all other 
Kv2.1 EIEE mutations that have been studied by voltage 
clamp (Torkamani et al., 2014) is not required for a 
disease phenotype.
periodic paralysis, benign familial neonatal seizures, pe-
ripheral nerve hyperexcitability, and EIEEs (Maljevic and 
Lerche, 2014). As human genetic data accumulates, 
general mechanistic origins of epileptic Kv channelopa-
thies may begin to emerge.
Similar to KCNB1, multiple KCNQ2 (Kv7.2) mutations 
have been found to be causative of EIEE (Dedek et al., 
2003; Weckhuysen et al., 2012). These two Kv channels 
have limited anatomical overlap in the brain. In central 
neurons, Kv7.2 is localized to axon initial segments and 
nodes of Ranvier where it mediates diverse aspects of 
axonal excitability (Devaux et al., 2004). Although the 
bulk of Kv2.1 is present in the plasma membrane of the 
soma and proximal dendrites, it is also expressed at 
high density on the axon initial segment in rodent and 
human brains (Sarmiere et al., 2008; King et al., 2014; 
Trimmer, 2015). The axon initial segment has high levels 
of Kv7.2 expression, and this neuronal subcellular com-
partment has been highlighted as a “hot spot” for epi-
leptogenesis, as mutations of many ion channels found 
here (e.g., Nav1.1/SCN1A, Nav1/SCN1B, Kv1.1/KCNA1, 
Kv7.2/KCNQ2, Kv7.3/KCNQ3, and GABA-A receptor 
2/GABRG2) give rise to epilepsy (Wimmer et al., 2010). 
Thus, Kv2.1/KCNB1 joins this list of ion channels local-
ized to the axon initial segment and associated with ep-
ilepsy-related mutations, raising the possibility that the 
epileptogenic effects of Kv2.1 mutation may arise from 
an electrical defect in the axon initial segment.
Figure 5. Coexpression of wild-type 
Kv2.1 C237 and Kv2.1 V378A results 
in intermediate surface expression lev-
els. (A) Cell surface expression of wild-
type Kv2.1 C237 (WT), Kv2.1 V378A 
(V378A), Kv2.1 V378A in the pres-
ence of wild-type Kv2.1 C237 (V378A 
Het), and wild-type Kv2.1 C237 in 
the presence of Kv2.1 V378A (WT Het) 
as determined by immunofluorescence 
in COS-1 cells, using antibodies that 
distinguish wild-type Kv2.1 C237 and 
Kv2.1 V378A. Data are from at least 
80 cells per independent sample (n = 
3 per treatment). Data are the mean 
± SEM. **, P < 0.01; ***, P < 0.001 (two-
tailed unpaired t test). (B) Multiplex 
immunofluorescence labeling for wild-
type Kv2.1 C237 (red), Kv2.1 V378A 
(green), and Hoechst 33258 (blue) in 
cells expressing wild-type Kv2.1 C237 
alone (top), expressing Kv2.1 V378A 
alone (middle), or expressing both sub-
units (bottom). Images were acquired 
with optimal exposure. Bar, 10 µm for 
all panels.
 Thiffault et al. 407
et al., 2009; Gupta et al., 2015). Through an endocytotic 
mechanism, GxTX could potentially access intracellular 
membranes and mediate rescue of the Golgi-localized 
V378A mutant via chaperone-like effects on channel 
folding, as observed in the pharmacological and chemical 
rescue of other intracellularly retained disease-associated 
ion channel mutants. Alternately, GxTX could rescue 
expression of the V378A mutant by binding surface 
channels and preventing internalization, either by sta-
bilizing their protein structure or by inhibiting their 
potentially toxic nonselective inward currents.
The patient described here is heterozygous for the 
de novo KCNB1 mutation that yields V378A Kv2.1. The 
distinct phenotypes of the V378A mutant, specifically 
alterations in both ion selectivity and subcellular local-
ization, are somewhat mitigated by coexpression with 
Kv2.1 isoforms with wild-type properties. This suggests 
that the Kv2.1 phenotype of the heterozygous patient 
may not be as drastically altered as it would be in a ho-
mozygous phenotype, and that within the tetrameric 
Kv2.1 channels, the mutant V378A subunits may exert 
dose-dependent as opposed to dominant effects on 
wild-type subunits. Detailed analyses of Kv2.1 channels 
with distinct subunit stoichiometries, of the type needed 
to determine how the subunit stoichiometry yields the 
distinct phenotypes of tetrameric channels, have not 
been performed. This could be achieved through ex-
tensive dose–response studies of wild-type and mutant 
subunits to bias their respective assembly into hetero-
meric channels with a predominance of wild-type or 
mutant subunits within the channel population, and 
the subsequent deconvolution of the expressed channel 
characteristics to determine the details of the channels 
with distinct characteristics (Ruppersberg et al., 1990; 
MacKinnon, 1991; Manganas and Trimmer, 2000), or 
generation of concatenated subunits to generate tetra-
meric channels with covalently defined subunit compo-
sitions (Sack et al., 2008). Future studies may reveal the 
nature of the impact of the growing number of diverse 
KCNB1 mutations associated with epileptic encephalop-
athies on heteromeric channels, as has been performed 
for other Kv channelopathies, for example, KCNA1 mu-
tations associated with episodic ataxia, for which muta-
tions with dominant, recessive, and haploinsufficiency 
phenotypes have been documented (Adelman et al., 
1995; Manganas et al., 2001a; Kullmann, 2002).
The cell type–specific differences in V378A traffick-
ing are reminiscent of Kv2.1 expression in different 
neuronal subpopulations of the mammalian brain. For 
instance, Kv2.1 clusters colocalize with ryanodine re-
ceptor–rich calcium signaling domains at the plasma 
membrane to a different extent in striatal and neocorti-
cal neurons (Mandikian et al., 2014), and in cultured 
hippocampal interneurons versus principal neurons 
(Antonucci et al., 2001). Additionally, steady-state levels 
of Kv2.1 phosphorylation also differ between different 
In addition to altered ion selectivity, our immuno-
cytochemistry experiments in transfected COS-1 cells 
reveal drastic changes in the subcellular localization of 
the human Kv2.1 V378A mutant, and a reduction of ap-
parent transfection efficiency. This could be a cellular 
response to a toxic inward current through V378A that 
triggers channel internalization and cell death, as these 
phenotypes are partially rescued by culturing cells in 
the Kv2 inhibitor GxTX. Additionally, the changes in 
V378A channel conductance result from structural de-
fects in the K+ channel selectivity filter, which could im-
pact the stability and localization of channel protein. 
Removal of K+ ions from the K+ channel pore leads to 
pore collapse (Zhou et al., 2001) and degradation of Kv 
channel proteins (Parcej and Dolly, 1989). Changes to 
the structure of the pore of Kv channels can also alter 
their trafficking (Manganas et al., 2001b; Vacher et al., 
2007). Synonymous defects in pore structure and local-
ization suggest caution in ascribing the pathophysiol-
ogy of the Kv2.1 pore mutations to channel conductance 
without taking into consideration possible effects on 
channel expression and localization.
Exogenous alteration of ion channel function can 
also alter channel localization. Inhibitors of ion chan-
nels have been shown to lead to pharmacological res-
cue of their normal expression patterns. Kv1 channel 
expression can be rescued by peptide inhibitors (Vacher 
et al., 2007; Rangaraju et al., 2010), similar to the effects 
of GxTX on Kv2.1 V378A channels in COS-1 cells. Phar-
macological rescue of expression has also been ob-
served for several other disease-associated ion channel 
mutations, most prominently mutant CFTR and HERG 
(KCNH2) channels, which result in cystic fibrosis (Cai 
et al., 2011) and cardiac arrhythmias (Balijepalli et al., 
2010), respectively. In these cases, pharmacological res-
cue has been primarily attributed to chaperone-like ef-
fects on biosynthetic folding of the mutant channels 
within the ER, leading to release from retention in the 
ER and cell surface expression (Leidenheimer and 
Ryder, 2014). A similar rescue of episodic ataxia-related 
Kv1.1 mutants is observed in response to treatment with 
general chemical chaperones (Manganas et al., 2001b), 
which are also presumed to act at the level of protein 
folding in the ER. These known mechanisms of rescue 
rely on treatments with membrane-permeable com-
pounds that can access intracellular compartments such 
as the ER. The mechanism underlying the pharmaco-
logical rescue of the V378A mutants in COS-1 cells, and 
the lack of rescue by GxTX in CHO-K1 cells, is not 
known. However, that GxTX rescued V378A expression 
in COS-1 cells, which have a substantial intracellular 
(Golgi) pool of mutant channels, versus CHO-K1 cells, 
which do not, is consistent with such an intracellular 
mechanism of pharmacological rescue. GxTX partitions 
into the outer leaflet of cell membranes, where it binds 
to membrane-facing regions of Kv2 channels (Milescu 
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neuronal subpopulations (Mandikian et al., 2014). Cell 
type–specific differences in the subcellular localiza-
tion of Kv2.1 channels are also observed in different 
heterologous cell backgrounds (Scannevin et al., 1996; 
Mohapatra and Trimmer, 2006). Our results suggest 
that expression and localization defects may contribute 
to the pathophysiological impact of disease-causing 
Kv2.1 mutations in a cell type–specific fashion. As Kv2.1 
channel localization plays a structural role in neurons in 
contributing to the formation of plasma membrane–ER 
junctions and recruiting junctional proteins including 
those involved in intracellular Ca2+ signaling (Antonucci 
et al., 2001; Fox et al., 2015), changes in Kv2.1 localiza-
tion could yield neurological consequences related to 
nonconducting functions of Kv2.1. The cell type–specific 
pharmacological rescue of the V378A variant indicates 
that effects on subcellular localization should be consid-
ered in therapeutic strategies targeting disease-causing 
Kv2.1 variants, as attempts to pharmacologically inhibit 
their aberrant depolarizing currents could inadver-
tently result in greater functional expression of disease-
causing channels.
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